Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northwest BiotherapeuticsNWBO -3.62%11 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Northwest Biotherapeutics ranks worse than 118905.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Northwest Biotherapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.49 Mil. Northwest Biotherapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Northwest Biotherapeutics Receivables Turnover Related Terms
Northwest Biotherapeutics Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NWBO vs LCTX, VRXA, ABEO: Receivables Turnover Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (NWBO) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Northwest Biotherapeutics and its competitors. According to the industry distribution chart, Northwest Biotherapeutics ranks #999999 out of 841 companies in the Biotechnology industry.
Is Northwest Biotherapeutics' Receivables Turnover too high?
Northwest Biotherapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Northwest Biotherapeutics ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Receivables Turnover compare to LCTX and VRXA?
According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #999999 out of 841 companies for Receivables Turnover. This places Northwest Biotherapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Northwest Biotherapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northwest Biotherapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score
Get the complete analysis for NWBO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NWBO has been successfully added to your 
